Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Biomarkers. 2012 Mar;17(2):186-91. doi: 10.3109/1354750X.2012.654511. Epub 2012 Feb 6.

Limitations of Chromogranin A in clinical practice.

Author information

  • 1Department of Molecular and Clinical Endocrinology and Oncology, Federico II University of Naples, Italy.

Abstract

CONTEXT:

Usefulness of circulating Chromogranin A (CgA) for the diagnosis of neuroendocrine tumors (NEN) is controversial. The aim of the present study was to assess the actual role of this marker as diagnostic tool.

METHODS:

Serum blood samples were obtained from 42 subjects affected with NEN, 120 subjects affected with non-endocrine neoplasias (non-NEN) and 100 non-neoplastic subjects affected with benign nodular goitre (NNG). Determination of CgA was performed by means of immunoradiometric assay.

RESULTS:

The CgA levels among NEN-patients were not significantly different from NNG and non-NEN subjects. The Receiver operating characteristic (ROC) curves analysis failed to identify a feasible cut-off value for the differential diagnosis between NEN and the other conditions.

CONCLUSION:

Serum CgA is not helpful for the first-line diagnosis of NEN.

PMID:
22303881
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk